자궁경부암 진단 시장 규모 : 진단 검사별, 연령대별, 최종사용자별 - 지역별 전망, 경쟁 전략, 부문별 예측(-2033년)

Cervical Cancer Diagnostic Market Size- By Diagnostic Test, By Age Group, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

US $ 4,250 ￦ 5,887,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인용 시에는 출처를 명시해 주시기 바랍니다

US $ 5,650 ￦ 7,826,000

PDF (Group License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 인용 시에는 출처를 명시해 주시기 바랍니다.

US $ 7,450 ￦ 10,320,000

PDF (Company License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 인용 시에는 출처를 명시해 주시기 바랍니다.

한글목차

세계 자궁경부암 진단 시장 규모는 2033년까지 5.28%의 CAGR을 기록하며 133억 7,000만 달러 규모로 성장할 것으로 예측됩니다.

2020년 COVID-19는 시장에 큰 영향을 미쳤고, 자궁경부암 진단 시장도 의료 서비스 중단으로 인해 어려움을 겪었습니다. COVID-19 사례 관리에 집중한 결과 자궁경부암 진단 건수가 감소하고, 많은 의료기관이 긴급하지 않은 수술과 검진을 지연시킴에 따라 정기 검진을 받는 여성의 수에 영향을 미쳤습니다.

세계 자궁경부암 진단 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추정 및 예측, 각 부문별·지역별·주요 국가별 상세 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

• 성장 촉진요인, 억제요인, 기회·과제 분석
• COVID-19의 시장에 대한 영향

제5장 시장 변수와 전망

• SWOT 분석
• PESTEL 분석
• Porter's Five Forces 분석
• 히트맵 분석

제6장 경쟁 상황

• 제조 거점 분포·판매 지역·제품 유형
• M&A·제휴·제품 발매·협력

제7장 세계의 자궁경부암 진단 시장 : 진단 검사별

• 세계 시장 규모·점유율·예측
• 팹 스미어 검사
• HPV 검사
• 생검·ECC
• 질경 검사
• 기타

제8장 세계의 자궁경부암 진단 시장 : 연령층별

• 세계 시장 규모·점유율·예측
• 20-40세
• 40세 이상

제9장 세계의 자궁경부암 진단 시장 : 최종사용자별

• 세계 시장 규모·점유율·예측
• 병원
• 전문 클리닉
• 암·방사선 치료 센터
• 진단 센터
• 기타

제10장 세계의 자궁경부암 진단 시장 예측

• 시장 규모·시장 점유율

제11장 세계의 자궁경부암 진단 시장 : 지역별

• 시장 규모·시장 점유율 추정과 예측
• 아시아태평양
• 유럽
• 중동 및 아프리카
• 북미
• 라틴아메리카

제12장 기업 개요

• Zilico
• Siemens Healthineers AG
• QIAGEN NV
• Abbott Laboratories
• Becton, Dickinson and Co.
• Quest Diagnostics Inc.
• F. Hoffmann-La Roche Ltd.
• Guided Therapeutics
• Hologic Inc.
• Bio-Rad Laboratories Inc.
• 기타

제13장 약어 리스트

제14장 참고 링크

제15장 결론

제16장 조사 범위

ksm

영문 목차

영문목차

Cervical Cancer Diagnostic Market Introduction and Overview

According to SPER market research, 'Cervical Cancer Diagnostic Market Size- By Diagnostic Test, Age Group, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Cervical Cancer Diagnostic Market is predicted to reach 13.37 billion by 2033 with a CAGR of 5.28%.

Cervical cancer is a type of cancer that originates in the cervix. The thinner, lower end of the uterus is known as the cervix (womb). The uterus and vagina are connected via the cervix. Typically, it develops gradually over time. Dysplasia occurs in the cells of the cervix before cervical cancer develops. It begins to reveal aberrant cells in the cervical tissue. If the abnormal cells are not cleared or killed, they may eventually grow into malignant cells that proliferate and spread throughout the cervix and surrounding tissues.

The 2020 COVID-19 pandemic had a significant impact on the market. Cervical cancer diagnostics market faced challenges because to the COVID-19 pandemic-related disruptions in healthcare services. Cervical cancer diagnostics decreased as a result of the focus on COVID-19 case management. A significant number of healthcare facilities delayed non-urgent surgeries and screenings, which in turn affected the number of women receiving routine testing.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Diagnostic Test, By Age Group, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Zilico, Siemens Healthineers AG, QIAGEN NV, Abbott Laboratories, Becton, Dickinson and Co, Quest Diagnostics Inc, F. Hoffmann-La Roche Ltd, Guided Therapeutics, Hologic Inc, Bio-Rad Laboratories.

Global Cervical Cancer Diagnostic Market Segmentation:

By Diagnostic Test: Based on the Diagnostic Test, Global Cervical Cancer Diagnostic Market is segmented as, Pap Smear Tests, HPV Test, Biopsy and ECC, Colposcopy Tests, Others.

By End User: Based on the End User, Global Cervical Cancer Diagnostic Market is segmented as; Hospitals, Speciality Clinics, Cancer and Radiation Therapy Centers, Diagnostic Centers, Others.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1. Research data source
  • 2.1.1. Secondary Data
  • 2.1.2. Primary Data
  • 2.1.3. SPER's internal database
  • 2.1.4. Premium insight from KOL's
• 2.2. Market size estimation
  • 2.2.1. Top-down and Bottom-up approach
• 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
  • 4.1.4. Challenges
• 4.2. COVID-19 Impacts of the Global Cervical Cancer Diagnostic Market.

5. Market variable and outlook

• 5.1. SWOT Analysis
  • 5.1.1. Strengths
  • 5.1.2. Weaknesses
  • 5.1.3. Opportunities
  • 5.1.4. Threats
• 5.2. PESTEL Analysis
  • 5.2.1. Political Landscape
  • 5.2.2. Economic Landscape
  • 5.2.3. Social Landscape
  • 5.2.4. Technological Landscape
  • 5.2.5. Environmental Landscape
  • 5.2.6. Legal Landscape
• 5.3. PORTER's Five Forces
  • 5.3.1. Bargaining power of suppliers
  • 5.3.2. Bargaining power of buyers
  • 5.3.3. Threat of Substitute
  • 5.3.4. Threat of new entrant
  • 5.3.5. Competitive rivalry
• 5.4. Heat Map Analysis

6. Competitive Landscape

• 6.1. Global Cervical Cancer Diagnostic Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cervical Cancer Diagnostic Market

7. Global Cervical Cancer Diagnostic Market, By Diagnostic Test (USD Million) 2020-2033

• 7.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2020-2026
• 7.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2027-2033
• 7.3. Pap Smear Tests
• 7.4. HPV Test
• 7.5. Biopsy and ECC
• 7.6. Colposcopy Tests
• 7.7. Others

8. Global Cervical Cancer Diagnostic Market, By Age Group (USD Million) 2020-2033

• 8.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2020-2026
• 8.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2027-2033
• 8.3. 20 to 40 years
• 8.4. above 40 years

9. Global Cervical Cancer Diagnostic Market, By End User (USD Million) 2020-2033

• 9.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2020-2026
• 9.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2027-2033
• 9.3. Hospitals
• 9.4. Specialty Clinics
• 9.5. Cancer and Radiation Therapy Centers
• 9.6. Diagnostic Centers
• 9.7. Others

10. Global Cervical Cancer Diagnostic Market Forecast, 2020-2033 (USD Million)

• 10.1. Global Cervical Cancer Diagnostic Market Size and Market Share

11. Global Cervical Cancer Diagnostic Market, By Region, 2020-2033 (USD Million)

• 11.1. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2020-2026)
• 11.2. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2027-2033)
• 11.3. Asia-Pacific
  • 11.3.1. Australia
  • 11.3.2. China
  • 11.3.3. India
  • 11.3.4. Japan
  • 11.3.5. South Korea
  • 11.3.6. Rest of Asia-Pacific
• 11.4. Europe
  • 11.4.1. France
  • 11.4.2. Germany
  • 11.4.3. Italy
  • 11.4.4. Spain
  • 11.4.5. United Kingdom
  • 11.4.6. Rest of Europe
• 11.5. Middle East and Africa
  • 11.5.1. Kingdom of Saudi Arabia
  • 11.5.2. United Arab Emirates
  • 11.5.3. Qatar
  • 11.5.4. South Africa
  • 11.5.5. Egypt
  • 11.5.6. Morocco
  • 11.5.7. Nigeria
  • 11.5.8. Rest of Middle-East and Africa
• 11.6. North America
  • 11.6.1. Canada
  • 11.6.2. Mexico
  • 11.6.3. United States
• 11.7. Latin America
  • 11.7.1. Argentina
  • 11.7.2. Brazil
  • 11.7.3. Rest of Latin America

12. Company Profile

• 12.1. Zilico
  • 12.1.1. Company details
  • 12.1.2. Financial outlook
  • 12.1.3. Product summary
  • 12.1.4. Recent developments
• 12.2. Siemens Healthineers AG
  • 12.2.1. Company details
  • 12.2.2. Financial outlook
  • 12.2.3. Product summary
  • 12.2.4. Recent developments
• 12.3. QIAGEN NV
  • 12.3.1. Company details
  • 12.3.2. Financial outlook
  • 12.3.3. Product summary
  • 12.3.4. Recent developments
• 12.4. Abbott Laboratories
  • 12.4.1. Company details
  • 12.4.2. Financial outlook
  • 12.4.3. Product summary
  • 12.4.4. Recent developments
• 12.5. Becton, Dickinson and Co.
  • 12.5.1. Company details
  • 12.5.2. Financial outlook
  • 12.5.3. Product summary
  • 12.5.4. Recent developments
• 12.6. Quest Diagnostics Inc.
  • 12.6.1. Company details
  • 12.6.2. Financial outlook
  • 12.6.3. Product summary
  • 12.6.4. Recent developments
• 12.7. F. Hoffmann-La Roche Ltd.
  • 12.7.1. Company details
  • 12.7.2. Financial outlook
  • 12.7.3. Product summary
  • 12.7.4. Recent developments
• 12.8. Guided Therapeutics
  • 12.8.1. Company details
  • 12.8.2. Financial outlook
  • 12.8.3. Product summary
  • 12.8.4. Recent developments
• 12.9. Hologic Inc.
  • 12.9.1. Company details
  • 12.9.2. Financial outlook
  • 12.9.3. Product summary
  • 12.9.4. Recent developments
• 12.10. Bio-Rad Laboratories Inc.
  • 12.10.1. Company details
  • 12.10.2. Financial outlook
  • 12.10.3. Product summary
  • 12.10.4. Recent developments
• 12.11. Others

13. List of Abbreviations

14. Reference Links

15. Conclusion

16. Research Scope

관련자료